[-] Show simple item record

dc.contributor.authorBlum, Nancyeng
dc.contributor.authorKamens, Cathyeng
dc.contributor.authorMayo, Helen G.eng
dc.date.issued2004eng
dc.description.abstractThere is considerable debate concerning the treatment of mild to moderate essential hypertension during pregnancy. Evidence suggests that because of the potential risk of fetal intrauterine growth restriction, treatment of hypertension should be delayed until maternal blood pressure reaches 150-160 mm Hg systolic or 100-110 mm Hg diastolic, as long as the mother has no preexisting end organ damage. Methyldopa has been the drug of choice for oral treatment, as it is the only medication to have any extended follow-up study. However, a recent meta-analysis raised the possibility of increased fetal mortality (strength of recommendation [SOR]: A, based on systematic review of randomized controlled trials).eng
dc.identifier.urihttp://hdl.handle.net/10355/3214eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2004 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri--Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 53, no. 06 (June 2004): 492-494.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectfetal mortalityeng
dc.subjectoral treatmenteng
dc.subjectfetal intrauterine growtheng
dc.subject.lcshHypertension in pregnancyeng
dc.subject.lcshMaternal Fetal Exchangeeng
dc.subject.lcshCardiovascular agents -- Toxicologyeng
dc.titleWhat treatments are safe and effective for mild to moderate hypertension in pregnancy?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record